- Home
- TVTX vs GLPG Comparison
TVTX vs GLPG Comparison
Compare TVTX & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- GLPG
- Stock Information
- Founded
- TVTX 2008
- GLPG 1999
- Country
- TVTX United States
- GLPG Belgium
- Employees
- TVTX N/A
- GLPG N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- TVTX Health Care
- GLPG Health Care
- Exchange
- TVTX Nasdaq
- GLPG Nasdaq
- Market Cap
- TVTX 1.8B
- GLPG 1.8B
- IPO Year
- TVTX N/A
- GLPG 2005
- Fundamental
- Price
- TVTX $21.98
- GLPG $26.74
- Analyst Decision
- TVTX Strong Buy
- GLPG Sell
- Analyst Count
- TVTX 12
- GLPG 5
- Target Price
- TVTX $30.08
- GLPG $26.75
- AVG Volume (30 Days)
- TVTX 1.8M
- GLPG 354.0K
- Earning Date
- TVTX 02-20-2025
- GLPG 02-12-2025
- Dividend Yield
- TVTX N/A
- GLPG N/A
- EPS Growth
- TVTX N/A
- GLPG N/A
- EPS
- TVTX N/A
- GLPG 1.16
- Revenue
- TVTX $233,175,000.00
- GLPG $285,380,474.00
- Revenue This Year
- TVTX $62.88
- GLPG $2.78
- Revenue Next Year
- TVTX $57.60
- GLPG $1.62
- P/E Ratio
- TVTX N/A
- GLPG $22.78
- Revenue Growth
- TVTX 60.55
- GLPG 14.99
- 52 Week Low
- TVTX $5.12
- GLPG $22.36
- 52 Week High
- TVTX $25.29
- GLPG $38.01
- Technical
- Relative Strength Index (RSI)
- TVTX 53.52
- GLPG 71.20
- Support Level
- TVTX $22.48
- GLPG $26.49
- Resistance Level
- TVTX $23.69
- GLPG $27.48
- Average True Range (ATR)
- TVTX 1.22
- GLPG 0.66
- MACD
- TVTX -0.02
- GLPG 0.54
- Stochastic Oscillator
- TVTX 41.10
- GLPG 85.55
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.